Science-First Collaborations: Ipsen’s Blueprint to External Innovation

David Jenkins, SVP and Head of External Innovation and Research, leads efforts to identify, evaluate and secure new programs across Ipsen’s three strategic areas of Oncology, Rare disease, and Neuroscience. He shares his insights on the essential role that collaboration, strategic partnerships, and a science-driven approach play in delivering scientific breakthroughs for patients.

Scientific innovation thrives on collaboration. From the global effort behind the Human Genome Project to the Nobel Prize-winning discoveries of Richard J. Roberts and Phillip A. Sharp whose research on split genes aided the understanding of some rare diseases — teamwork has consistently driven major breakthroughs. At Ipsen, this principle is particularly vital, as we are building our pipeline exclusively through external partnerships. This strategic choice allows us to work alongside some of the best innovators in life-sciences to deliver life-changing treatments to patients. 

Our external innovation strategy is guided by three core principles: being science driven, prioritizing patient impact, and focusing on precision medicine. With this in mind, our bar is set to best- or first-in-class innovation supported by compelling scientific rationale within our three focus areas: Oncology, Rare disease, and Neuroscience. The foundation of this strategy is built on strong collaboration, which allows us to leverage our united expertise to achieve a shared scientific vision. By focusing on precision medicine and targeting niche areas of disease with high unmet medical needs, we aim to make a significant impact on underserved populations. Our execution of biomarker-driven clinical trials allows us to swiftly identify efficacy signals and make data-driven decisions to accelerate the advancement of the most promising assets.

Our collaborative approach combines the strengths of both Ipsen and our partners, pushing the boundaries beyond what we could achieve separately. Our partners bring strong science and a deep understanding of their therapy areas of focus, throughout the development process. We contribute our expertise in translational, CMC (Chemistry, Manufacturing, and Controls), global clinical development and regulatory. Together, we continue to build a balanced portfolio between established and emerging areas of science, striking the right balance between risk and ability to deliver proof of concept in early clinical development. By maintaining a mix of novel and established modalities in our expanding pipeline, we are well-positioned to advance transformative treatments.

Ipsen’s commitment to collaboration drives our innovation and ensures we are consistently at the forefront of delivering breakthrough therapies to those who need them most. By continually refining our focus and working hand-in-hand with leading innovators, we are not just advancing our pipeline – we are paving the way for the next generation of breakthrough therapies that will transform the lives of patients worldwide.

By partnering with others who share your vision and complement your strengths, you can unlock new possibilities that would have been impossible alone. When will you next seek a partnership that pushes boundaries?